1 comment

  1. The best is yet to come: "When PD-1 mAb blockade was administered concomitantly with DC vaccination, a highly significant survival benefit resulted. Approximately 40% long-term survival was observed selectively in the combination treatment group (Figure 2D). As we described before, there was no therapeutic benefit with DC vaccination alone in these large, established tumors. Similarly, there was no survival benefit noted with PD-1 mAb blockade alone."
    JCI Insight. 2016;1(10):e87059. doi:10.1172/jci.insight.87059.

Leave a Reply

(*) Required, Your email will not be published